Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
about
Emerging drugs for uveitisVogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytesCurrent concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.Cyclophosphamide for ocular inflammatory diseasesCyclosporine for ocular inflammatory diseases.Mycophenolate mofetil for ocular inflammation.Pharmacotherapy for uveitis: current management and emerging therapy.Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.Success with single-agent immunosuppression for multifocal choroidopathies.Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory diseaseTreatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.Corticosteroid-sparing therapy: practice patterns among uveitis specialistsRemission of Intermediate Uveitis: Incidence and Predictive FactorsQuality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid TrUveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.Systemic lupus erythematosus, pregnancy and carcinoma of the tongue.Methotrexate for ocular inflammatory diseases.Azathioprine for ocular inflammatory diseases.Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys.Squamous cell carcinoma on the palate in a patient with systemic lupus erythematosus: case report and review of literature.Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.Side-effects of anti-inflammatory therapy in uveitis.Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.Pharmacologic Treatment of Noninfectious Uveitis.Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.Treatment of uveitis: beyond steroids.Immunosuppression for the Uveitides.Recurrence of uveitis after discontinuation of infliximab.[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].[Anti-TNF-α treatment for uveitis. Analysis of the current situation].Efficacy and adverse reactions of methotrexate in the treatment of ocular cicatricial pemphigoid: A case series study
P2860
Q24630848-B7F42029-BA01-4B5D-BB12-70249D294443Q26752297-E88FE934-7CBA-4B2C-AF6E-988CD8F76744Q27693189-593A451E-B086-4268-AE09-38436E177716Q33478325-42DB353F-3401-4F6E-B04D-A17BCB25FD12Q33517496-7FD052FC-67AD-4E6F-B841-44362474A798Q33520584-7106E5B7-3729-49FB-9D28-3F5B881D5FE2Q33521396-2C436475-7C0A-43C1-9BFB-C18E9777AFD8Q34274075-6A2B4092-B15D-4F85-8C6E-4E4328721638Q34444734-6A9C5DCE-73EE-4E15-A145-1BCD482F0080Q34623981-02A596BF-5A8A-4386-9C23-0A090B46BD5EQ34630641-FEC6E51A-826E-4E4A-9DDD-C0650D9214C9Q35176767-D0B5624C-B48E-45F6-8915-1F5177763D90Q35215459-588DA463-EDAC-4754-B319-FAFDF72C95DDQ35221140-41C5933D-F9C3-4B08-B135-791048E1C321Q35233322-276730DB-474C-4666-BAC2-165B41DB7F9EQ35828102-423048A6-C733-4538-96BD-E1787D356877Q35895632-956C6188-C854-4620-A94E-DEE32F51BD9BQ36090279-74F2F7AD-AD7F-49CE-8198-376BF58C8A19Q36174993-AD12AF46-9B27-4096-A941-CB2794C17E64Q36893850-907E936D-F0E1-4132-9B9F-E868BF2EAE44Q37204512-C43800B9-5765-4AD6-A67D-D3A00E9DECF3Q37366679-5AF50B9B-0D66-4CEB-854F-957AAB68310FQ37406600-691D57A3-EB59-4F17-B722-25EDF6029542Q37692472-1A855BD7-A05E-4E8E-8162-9F6F95722BADQ37819551-B7554675-3070-4FD1-854C-CC53630F474AQ37956187-6918CE57-ABAC-4C14-AE71-D59742001639Q38184630-75DFA5E1-41DB-44C6-B7E4-14C4BE7D3A30Q38250103-A3C1685A-4234-4093-9A83-AF5BDDE3E1BCQ38250116-DCB7CA9A-C7E1-4D63-9C52-EF5F112E6B9BQ38261127-DCF2D4AA-D5FD-4276-8593-50722FD027ABQ38464355-B3054A1D-EEB8-4F3B-94C5-B8190A0AD301Q40450258-091F6221-4617-420C-8D50-3BFB06165C15Q42292365-3194A549-6FE3-4372-8345-2F6D6E4E73C0Q42359937-5CC912CB-F4D3-4E7B-8D5B-6BA28D6293C8Q42867486-1DA95ACC-B423-4D52-817E-EDBBF1FA5915Q47932596-3C733039-BB9E-4CCC-9C33-2D85F833AA41Q47959278-B0C465E0-2EB4-44E3-9A12-ECA22A761F25Q49845401-46A1B8CA-4B31-4AE8-A5E8-1820C645E056Q52899661-17D25A4E-0C89-4253-B3C0-E8227DEF9C0AQ58704407-12139784-CE5C-4960-A099-E1831501FC76
P2860
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Long-term risk of malignancy a ...... al assessment of the evidence.
@ast
Long-term risk of malignancy a ...... al assessment of the evidence.
@en
type
label
Long-term risk of malignancy a ...... al assessment of the evidence.
@ast
Long-term risk of malignancy a ...... al assessment of the evidence.
@en
prefLabel
Long-term risk of malignancy a ...... al assessment of the evidence.
@ast
Long-term risk of malignancy a ...... al assessment of the evidence.
@en
P2093
P2860
P50
P1476
Long-term risk of malignancy a ...... al assessment of the evidence.
@en
P2093
C Stephen Foster
Douglas A Jabs
Eric B Suhler
James T Rosenbaum
Jennifer E Thorne
John H Kempen
Kathy J Helzlsouer
Sapna Gangaputra
P2860
P304
P356
10.1016/J.AJO.2008.04.035
P407
P577
2008-06-25T00:00:00Z